Trial reportBritish journal of cancer2024
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.
Trial report in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00116935 (Short), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence
Who cites it
11 citing papers in PubMed.
- Adjuvant treatment of gastrointestinal stromal tumors (GIST)-state of the art, controversies, and future directions.ESMO gastrointestinal oncology · 2026Review
- Comparison of nomograms and predictive tools in gastrointestinal stromal tumor.Journal of gastrointestinal oncology · 2026Article
- A Rare Case of Multifocal Ileal and Mesenteric Gastrointestinal Stromal Tumors With Spontaneous Rupture.Cureus · 2026Article
- Laparoscopic and endoscopic cooperative surgery in gastrointestinal tumors: current applications, oncologic considerations, and future directions.Frontiers in oncology · 2026Review
- A Case of Solitary Fibrous Tumor with Tumor Rupture during the Waiting Period for Elective Surgery.Surgical case reports · 2026Article
- The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib.Journal of clinical medicine · 2026Review
- Article
- Case Report: a giant gastric stromal tumor spontaneously hemorrhaged after freeze-dried rabies vaccine (Vero-cells) injection for human use.Frontiers in oncology · 2026Article
- Spontaneous Terminal Ileum GIST Perforation Causing an Acute Abdomen in an Elderly Patient-A Rare Case.Diagnostics (Basel, Switzerland) · 2025Article
- Minimally invasive approaches to small gastric stromal tumors: The less with the more.World journal of gastrointestinal surgery · 2025Article
- What kind of tumour rupture requires adjuvant therapy?British journal of cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPatients with ruptured gastrointestinal stromal tumour (GIST) have poor prognosis. Little information is available about how adjuvant imatinib influences survival.
methodsWe explored recurrence-free survival (RFS) and overall survival (OS) of patients with ruptured GIST who participated in a randomised trial (SSG XVIII/AIO), where 400 patients with high-risk GIST were allocated to adjuvant imatinib for either 1 year or 3 years after surgery. Of the 358 patients with confirmed localised GIST, 73 (20%) had rupture reported. The ruptures were classified retrospectively using the Oslo criteria.
resultsMost ruptures were major, four reported ruptures were reclassified unruptured. The 69 patients with rupture had inferior RFS and OS compared with 289 patients with unruptured GIST (10-year RFS 21% vs. 55%, OS 59% vs. 78%, respectively). Three-year adjuvant imatinib did not significantly improve RFS or OS of the patients with rupture compared with 1-year treatment, but in the largest mutational subset with KIT exon 11 deletion/indel mutation OS was higher in the 3-year group than in the 1-year group (10-year OS 94% vs. 54%).
conclusionsAbout one-fifth of ruptured GISTs treated with adjuvant imatinib did not recur during the first decade of follow-up. Relatively high OS rates were achieved despite rupture. CLINICAL
trial registrationNCT00116935.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.